Esperion Therapeutics Stock Forecast, Price & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last twelve months. There are currently 2 sell ratings, 5 hold ratings, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Esperion Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESPR, but not buy additional shares or sell existing shares.
View analyst ratings for Esperion Therapeutics or view top-rated stocks.

Wall Street analysts have given Esperion Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Esperion Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Esperion Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Esperion Therapeutics.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) released its quarterly earnings data on Tuesday, May, 4th. The biopharmaceutical company reported ($3.50) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($2.08) by $1.42. The biopharmaceutical company had revenue of $8 million for the quarter, compared to analyst estimates of $34.28 million. Esperion Therapeutics had a negative net margin of 46.15% and a negative trailing twelve-month return on equity of 629.88%. The firm's revenue was up 344.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($2.84) EPS.
View Esperion Therapeutics' earnings history.

Esperion Therapeutics' stock was trading at $42.93 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ESPR shares have decreased by 48.8% and is now trading at $21.97.
View which stocks have been most impacted by COVID-19.

10 brokers have issued 1 year target prices for Esperion Therapeutics' stock. Their forecasts range from $20.00 to $134.00. On average, they anticipate Esperion Therapeutics' share price to reach $49.27 in the next year. This suggests a possible upside of 124.3% from the stock's current price.
View analysts' price targets for Esperion Therapeutics or view top-rated stocks among Wall Street analysts.

20 employees have rated Esperion Therapeutics CEO Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among Esperion Therapeutics' employees.

Some companies that are related to Esperion Therapeutics include ALX Oncology (ALXO), Corcept Therapeutics (CORT), Global Blood Therapeutics (GBT), Prestige Consumer Healthcare (PBH), Organogenesis (ORGO), OPKO Health (OPK), Xencor (XNCR), Madrigal Pharmaceuticals (MDGL), Ligand Pharmaceuticals (LGND), Axsome Therapeutics (AXSM), IGM Biosciences (IGMS), NGM Biopharmaceuticals (NGM), Dicerna Pharmaceuticals (DRNA), Seres Therapeutics (MCRB) and Arcus Biosciences (RCUS).
View all of ESPR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include (ALDW) (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), The Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn).

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

Esperion Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wasatch Advisors Inc. (14.61%), BlackRock Inc. (7.61%), Rafferty Asset Management LLC (0.39%), GAM Holding AG (0.25%), Swiss National Bank (0.21%) and Rhumbline Advisers (0.11%). Company insiders that own Esperion Therapeutics stock include Target N V Biotech and Timothy M Mayleben.
View institutional ownership trends for Esperion Therapeutics.

ESPR stock was sold by a variety of institutional investors in the last quarter, including Hamilton Lane Advisors LLC, Los Angeles Capital Management LLC, Russell Investments Group Ltd., US Bancorp DE, Alliancebernstein L.P., Rhumbline Advisers, Pacer Advisors Inc., and State Board of Administration of Florida Retirement System.
View insider buying and selling activity for Esperion Therapeutics or view top insider-selling stocks.

ESPR stock was acquired by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., BlackRock Inc., Rafferty Asset Management LLC, GAM Holding AG, EMC Capital Management, Resources Investment Advisors LLC., Symons Capital Management Inc., and Arizona State Retirement System. Company insiders that have bought Esperion Therapeutics stock in the last two years include Target N V Biotech, and Timothy M Mayleben.
View insider buying and selling activity for Esperion Therapeutics or or view top insider-buying stocks.

Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ESPR stock can currently be purchased for approximately $21.97.

Esperion Therapeutics has a market capitalization of $619.38 million and generates $148.36 million in revenue each year. The biopharmaceutical company earns $-97,170,000.00 in net income (profit) each year or ($3.59) on an earnings per share basis.

Esperion Therapeutics employs 479 workers across the globe.

The official website for Esperion Therapeutics is www.esperion.com.

Esperion Therapeutics is headquartered at 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108.

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at 734-887-3903 or via email at [email protected]